journal article·2024-09-04

Self-Healing Hydrogel Resulting from the Noncovalent Interaction between Ropivacaine and Low-Molecular-Weight Gelator Sodium Deoxycholate Achieves Stable and Endurable Local Analgesia in Vivo

Xin Tan, Yi Zhou, Yaxin Qin, Linjie Wu, Ruizhi Yang, Xiaoyan Bao, Ruolin Jiang, Xiaoyan Sun, Xufang Ying, Zhiqing Ben, Qi Dai, Zhicheng Zhang, Kai Zeng, Min Han

ACS Applied Materials & Interfaces· Volume 16· Issue 35
Publisher page

Abstract

Regional analgesia based on the local anesthetic ropivacaine plays a crucial role in postoperative pain management and recovery; however, the short duration of analgesia limits its clinical potential. Various drug delivery systems such as microparticles and lipid carriers have been used to prolong the analgesic effect, yet most of them are prone to abrupt release from the site of administration or have poor analgesic effects of less than 48 h, which fail to meet the needs of postoperative analgesia. In this study, a low-molecular-weight gelator sodium deoxycholate-based hydrogel loaded with ropivacaine (DC-ROP gel) was designed for long-acting analgesia. The noncovalent interaction between ropivacaine and sodium deoxycholate helps to improve the stability and sustained release performance of the gel. This internal drug-binding hydrogel also avoids experiencing the burst release effect commonly seen in polymer hydrogels previously reported for the slow release of local anesthetics. DC-ROP gel exhibited the dual advantages of self-healing after compression and long-term controlled release. In mice with inflammatory pain, DC-ROP gel achieved peripheral nerve block for more than 1 week after a single injection. Histological and blood biochemical analyses confirmed that the DC-ROP gel did not produce systemic toxicity, and cytotoxicity experiments demonstrated that the DC-ROP gel resulted in low irritation. These results suggest that DC-ROP gel provides a promising strategy for local anesthetics in long-term postoperative pain management, broadening the potential of bile salt-based low-molecular-weight hydrogels for drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Anesthesia and Pain Management · Pain Mechanisms and Treatments · Neuropeptides and Animal Physiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

National Narcotic Laboratory Zhejiang Regional Center, Hangzhou 310000, China

Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China

Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310058, China

Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, PR China

National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province

References (68)

Show source-provided references
1. 10.2174/187443460110501005210.2174/1874434601105010052 ↗
2. 10.1097/ALN.000000000000368110.1097/ALN.0000000000003681 ↗
3. 10.1016/j.anclin.2022.04.00210.1016/j.anclin.2022.04.002 ↗
4. 10.1007/s11916-022-01062-610.1007/s11916-022-01062-6 ↗
5. 10.1213/ANE.000000000000401810.1213/ANE.0000000000004018 ↗
6. 10.2344/0003-3006-59.2.9010.2344/0003-3006-59.2.90 ↗
7. 10.1021/acsami.1c0089410.1021/acsami.1c00894 ↗
8. 10.1016/j.anclin.2022.05.00210.1016/j.anclin.2022.05.002 ↗
9. 10.1097/ACO.000000000000092810.1097/ACO.0000000000000928 ↗
10. 10.2147/DDDT.S29122910.2147/DDDT.S291229 ↗
11. 10.1038/s41582-020-00415-210.1038/s41582-020-00415-2 ↗
12. 10.1002/advs.20210523110.1002/advs.202105231 ↗
13. 10.1093/nsr/nwac10410.1093/nsr/nwac104 ↗
14. 10.1002/lpor.20240003510.1002/lpor.202400035 ↗
15. 10.1038/s41598-021-91624-210.1038/s41598-021-91624-2 ↗
16. 10.1016/j.ejpb.2021.01.01510.1016/j.ejpb.2021.01.015 ↗
17. 10.1208/s12249-020-01878-810.1208/s12249-020-01878-8 ↗
18. 10.1002/cmdc.20230000910.1002/cmdc.202300009 ↗
19. 10.1016/j.drudis.2018.06.01910.1016/j.drudis.2018.06.019 ↗
20. 10.1016/j.actbio.2019.05.04910.1016/j.actbio.2019.05.049 ↗
21. 10.1136/rapm-2020-10242710.1136/rapm-2020-102427 ↗
22. 10.1007/s00101-022-01118-710.1007/s00101-022-01118-7 ↗
23. 10.1016/j.biomaterials.2023.12212910.1016/j.biomaterials.2023.122129 ↗
24. 10.1016/j.actbio.2017.11.05710.1016/j.actbio.2017.11.057 ↗
25. 10.1016/j.biomaterials.2012.12.03510.1016/j.biomaterials.2012.12.035 ↗
26. 10.1016/j.ijpharm.2019.01.01110.1016/j.ijpharm.2019.01.011 ↗
27. 10.1021/acs.chemrev.0c0117710.1021/acs.chemrev.0c01177 ↗
28. 10.1016/S0378-5173(99)00170-210.1016/S0378-5173(99)00170-2 ↗
29. 10.1021/jp402949710.1021/jp4029497 ↗
30. 10.1070/RCR468210.1070/RCR4682 ↗
31. 10.1021/acs.langmuir.6b0305210.1021/acs.langmuir.6b03052 ↗
32. 10.1016/j.jcis.2019.07.01910.1016/j.jcis.2019.07.019 ↗
33. 10.1039/C8QM00612A10.1039/C8QM00612A ↗
34. 10.1016/j.biomaterials.2017.08.03410.1016/j.biomaterials.2017.08.034 ↗
35. 10.1016/j.jcis.2021.06.14010.1016/j.jcis.2021.06.140 ↗
36. 10.1080/17425247.2016.117823310.1080/17425247.2016.1178233 ↗
37. 10.1021/acssuschemeng.8b0511210.1021/acssuschemeng.8b05112 ↗
38. 10.1039/C4RA13353F10.1039/C4RA13353F ↗
39. 10.3390/pharmaceutics1211106910.3390/pharmaceutics12111069 ↗
40. 10.1016/j.ijpharm.2010.10.03610.1016/j.ijpharm.2010.10.036 ↗
41. 10.1039/C9NA00308H10.1039/C9NA00308H ↗
42. 10.1038/s41583-021-00536-710.1038/s41583-021-00536-7 ↗
43. 10.1016/0165-0270(94)90144-910.1016/0165-0270(94)90144-9 ↗
44. 10.1038/s41467-019-10296-910.1038/s41467-019-10296-9 ↗
45. 10.1016/j.colsurfa.2022.12831610.1016/j.colsurfa.2022.128316 ↗
46. 10.1080/03639045.2022.210699510.1080/03639045.2022.2106995 ↗
47. 10.1016/j.pharmthera.2013.01.00610.1016/j.pharmthera.2013.01.006 ↗
48. 10.1021/acs.langmuir.1c0217510.1021/acs.langmuir.1c02175 ↗
49. 10.1016/j.colsurfa.2014.06.00310.1016/j.colsurfa.2014.06.003 ↗
50. 10.1007/s12274-022-5129-110.1007/s12274-022-5129-1 ↗
51. 10.1021/la011178h10.1021/la011178h ↗
52. 10.1038/s41598-019-44233-z10.1038/s41598-019-44233-z ↗
53. 10.1016/j.ijpharm.2024.12437810.1016/j.ijpharm.2024.124378 ↗
54. 10.3390/ma1103045410.3390/ma11030454 ↗
55. 10.1021/acs.langmuir.6b0001910.1021/acs.langmuir.6b00019 ↗
56. 10.1021/acs.chemrev.2c0017910.1021/acs.chemrev.2c00179 ↗
57. 10.1039/D3MH00891F10.1039/D3MH00891F ↗
58. 10.1039/c9pp00293f10.1039/c9pp00293f ↗
59. 10.1016/j.colsurfb.2020.11080310.1016/j.colsurfb.2020.110803 ↗
60. 10.1016/j.jpba.2009.11.01310.1016/j.jpba.2009.11.013 ↗
61. 10.1002/jps.2149610.1002/jps.21496 ↗
62. 10.2147/IJN.S36970610.2147/IJN.S369706 ↗
63. 10.1523/ENEURO.0115-15.201510.1523/ENEURO.0115-15.2015 ↗
64. 10.1007/s10753-021-01418-x10.1007/s10753-021-01418-x ↗
65. 10.1039/C8RA05358H10.1039/C8RA05358H ↗
66. 10.1039/c2jm34016j10.1039/c2jm34016j ↗
67. 10.1021/acsomega.8b0355510.1021/acsomega.8b03555 ↗
68. 10.1136/rapm-2019-10071410.1136/rapm-2019-100714 ↗